RESEARCH MONOGRAPH · KDC-MN-157

Kava (Piper methysticum)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

67/100

Real anxiolytic signal, real hepatotoxicity questions, and the chemotype matters more than people realize

Kava is one of those botanicals where the pharmacology is actually pretty interesting and the marketing has totally fumbled it. The active fraction is the kavalactones, mostly kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin. They hit GABA-A allosterically (different site than benzodiazepines), modulate voltage-gated sodium channels, weakly inhibit MAO-B, and there's some sigma-1 activity too. So it's not a one-mechanism story.

The anxiety RCT evidence is genuinely there. Sarris and the Australian groups have run multiple human trials on aqueous extracts standardized to ~70-250mg kavalactones, and the effect sizes for generalized anxiety are real, replicated, and competitive with low-dose benzos without the dependence profile. That's not a small claim.

The hepatotoxicity story is messier than either side admits. The 2002 European bans came after maybe 30 case reports against millions of users, and a lot of those reports involved acetone or ethanol extracts of aerial parts or peelings (the bad part of the plant). Traditional Pacific preparations use noble cultivar roots in water and the safety record across centuries is fine. So when you see a kava paper, the FIRST thing we look at is chemotype (noble vs tudei) and extraction solvent.

Tudei chemotype is the trap. Higher flavokavain B, longer half-life, hangover-style next-day grogginess, and probably most of the hepatotox signal. Noble kava is a different animal.

Sourcing-wise this is where most vendors fail. We want noble cultivar, root only, aqueous or ethanol-aqueous extract, HPLC kavalactone profile disclosed. Honestly most supplement-grade kava is opaque about all of this.

What we like: actual mechanism, actual human data, actual cultural validation. What we dont like: the constant conflation of noble traditional preparations with cheap aerial-parts tudei extracts, and the fact that most research papers dont even specify which they used.

Worth keeping in the library? yeah. Just treat the chemotype question as load-bearing, not as a footnote.

Evidence: 72
Mechanism: 70
Reliability: 70
Safety: 62
Sourcing: 55
Value: 65
Signal: 75
Staying power: 70

Plain-language summary Intrigue 60 / 100

Kava (Piper methysticum) is a Pacific Island plant traditionally used for ceremonial and social purposes. The kavalactones produce GABAergic anxiolytic effects without the dependence of benzodiazepines. Hepatotoxicity is a documented concern with low-quality preparations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Pacific Island botanical / kavalactone source

A Pacific Island root containing kavalactones with anxiolytic, sedative, and muscle-relaxant activity through GABA-A modulation and other mechanisms.

Abstract

Kava (Piper methysticum) is a perennial shrub native to the Pacific Islands whose root has been used ceremonially and medicinally for centuries. The active constituents are kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin); the kavalactone profile varies among kava cultivars (the "noble" cultivars with kavain-dominant profiles being preferred for traditional use). Pharmacology includes GABA-A receptor modulation, voltage-gated sodium channel inhibition, and dopamine receptor effects. Hepatotoxicity has been reported with kava products, leading to bans in some European jurisdictions; the toxicity has been linked to particular cultivars or extraction methods rather than kava per se. Reported research dose ranges in the literature span 100 to 250 mg kavalactones.

Mechanism of action

Kavalactones with multiple targets: GABA-A modulation, voltage-gated sodium channel inhibition, dopamine effects.

Reported research dose ranges

Reported research dose ranges in the literature span 100 to 250 mg kavalactones.

References

Sarris J, et al. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2013.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-157

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Kava (Piper methysticum)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs